Survival Benefit of Neoadjuvant Treatment in Clinical T3N0M0 Esophageal Cancer: Results From a Retrospective Multicenter European Study.

@article{Mantziari2017SurvivalBO,
  title={Survival Benefit of Neoadjuvant Treatment in Clinical T3N0M0 Esophageal Cancer: Results From a Retrospective Multicenter European Study.},
  author={Styliani Mantziari and Caroline Gronnier and Florence Renaud and Alain Duhamel and J Thereaux and C{\'e}cile Brigand and Nicolas Carr{\`e}re and Jeremie H Lefevre and Arnaud Pasquer and Nicolas Demartines and Denis Collet and Bernard Meunier and Christophe Mariette},
  journal={Annals of surgery},
  year={2017},
  volume={266 5},
  pages={805-813}
}
BACKGROUND Based on current guidelines, clinical T3N0M0 esophageal tumors may or may not receive neoadjuvant treatment, according to their perception as locally advanced (cT3) or early-stage tumors (stage II). The study aim was to assess the impact of neoadjuvant treatment upon survival for cT3N0M0 esophageal cancer patients, with subgroup analyses by histological type (squamous cell carcinoma vs adenocarcinoma) and type of neoadjuvant treatment (chemotherapy vs radiochemotherapy). METHODS… CONTINUE READING